

Next Steps

Refer to the manual for the destination vector you are using for guidelines and instructions to express your recombinant protein in the appropriate system.

For more information on Gateway® MultiSite Technology, see the Gateway® Technology, MultiSite Gateway® and MultiSite Gateway® Pro manuals, available at www.invitrogen.com.

Quality Control

LR Clonase™ II Plus enzyme mix is functionally tested in a 16-hour reaction to combine 4 fragments into one DEST vector, followed by a transformation assay.

References

1. Landy, A. (1989) *Ann. Rev. Biochem.* 58, 913.

Limited Use Label License No. 19: Gateway® Cloning Products

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for profit entity). The purchase of this product does not convey a license under any method claims in the foregoing patents or patent applications, or to use this product with any recombination sites other than those purchased from Invitrogen Corporation or its authorized distributor. The right to use methods claimed in the foregoing patents or patent applications with this product for research purposes only can only be acquired by the use of Clonase™ purchased from Invitrogen Corporation or its authorized distributors. The buyer cannot modify the recombination sequence(s) contained in this product for any purpose. The buyer cannot sell or otherwise transfer (a) this product, (b) its components, or (c) materials made by the employment of this product or its components to a third party or otherwise use this product or its components or materials made by the employment of this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the employment of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Notwithstanding the preceding, any buyer who is employed in an academic or government institution may transfer materials made with this product to a third party who has a license from Invitrogen under the patents identified above to distribute such materials. Transfer of such materials and/or information to collaborators does not convey rights to practice any methods claimed in the foregoing patents or patent applications. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that none of (i) this product, (ii) any of its components, or (iii) a method claim of the foregoing patents, was used in the manufacture of such product. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the use of this product to manufacture a protein for sale, provided that no method claim in the above patents was used in the manufacture of such protein. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to use this product for purposes other than those permitted above, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200.

©2006 Invitrogen Corporation. All rights reserved.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.

Gateway® LR Clonase™ II Plus Enzyme Mix

Cat. No. 12538-120

Cat. No. 12538-200

Size: 20 reactions

Size: 100 reactions

MultiSite Gateway® and MultiSite Gateway® Pro

MultiSite Gateway® and MultiSite Gateway® Pro are extensions of the Gateway® site-specific recombinational cloning technology, which is based on the recombination properties of bacteriophage lambda (1). MultiSite Gateway® allows cloning of exactly three DNA fragments into pDEST R4R3, while MultiSite Gateway® Pro allows cloning of two, three, or four DNA fragments in a defined order and orientation into any pDEST vector containing *attR1* and *attR2* sites. Both systems provide a rapid and efficient way to recombine DNA elements into vector systems for functional analysis and protein expression. The LR recombination reaction occurs between two specific attachment sites (*attL* and *attR*) on the entry clones and the destination vector, allowing the recombination of fragments into the destination vector. The reaction is mediated by Gateway® LR Clonase™ II Plus enzyme mix.

Gateway® LR Clonase™ II Plus

Gateway® LR Clonase™ II Plus enzyme mix is a proprietary enzyme formulation specifically designed for MultiSite Gateway® and MultiSite Gateway® Pro. Gateway® LR Clonase™ II Plus enzyme mix contains the bacteriophage lambda recombination proteins Integrase (Int) and Excisionase (Xis), and the *E. coli*-encoded protein Integration Host Factor (IHF) (1), and reaction buffer provided in a single mix for convenient reaction set up. Gateway® LR Clonase™ II Plus enzyme mix promotes *in vitro* recombination between *attL*- and *attR*-flanked regions on entry clones and destination vectors to generate *attB*-containing expression clones.

Component

	<u>20 rxns</u>	<u>100 rxns</u>
Gateway® LR Clonase™ II Plus Enzyme Mix	40 µl	200 µl
2 µg/µl Proteinase K Solution	40 µl	200 µl

Storage

Store Gateway® LR Clonase™ II Plus at -20°C (in a non-frost-free freezer) for up to 6 months. For long term storage, store at -80°C

Part no. 12538.pps

Rev. date: 11 July 2006

General Recommendations and Guidelines

- We recommend using plasmid DNA purified with the PureLink™ HiPure Plasmid Midiprep Kit (Catalog no. K2100-04). Mini-prep (alkaline lysis) DNA preparations are **not recommended** for MultiSite Gateway® cloning reactions. DNA cannot be quantitated by UV absorbance due to contaminating RNA and nucleotides, estimate concentration by gel electrophoresis (*e.g.*, DNA Mass Ladder, Cat. no. 10068-013 or 10496-016).
- For LR reactions, supercoiled entry vectors and destination vectors provide efficient substrates.
- For large (>10 kb) entry clones or destination vectors, linearizing the entry clone or destination vector may increase the efficiency by up to two fold.

To Convert fmoles to nanograms (ng)

$$\text{ng} = (x \text{ fmol})(N) \left(\frac{660 \text{ fg}}{\text{fmol}} \right) \left(\frac{1 \text{ ng}}{10^6 \text{ fg}} \right)$$

where N is the size of the DNA in base pairs, and x is the number of fmoles

MultiSite Gateway® and MultiSite Gateway® Pro LR Reaction Mixture

For multi-fragment (*i.e.* 2-, 3-, or 4-fragment recombination) reactions, use an equimolar amount of each entry clone. We recommend 10 fmol of **each** entry clone and 20 fmol of DEST vector per 10 µl reaction.

Note: If you are using MultiSite Gateway®, you can only recombine three entry clones into pDEST R4R3. If you are using MultiSite Gateway® Pro, you can recombine up to four entry clones into any pDEST vector containing *attR1* and *attR2* sites.

Add the following components to a 1.5-ml microcentrifuge tube at room temperature and mix. Use this reaction mixture in the **Procedure** on the next page.

Entry clones (10 fmoles)	1-7 µl total*
Destination vector (20 fmoles)	1 µl
1X TE buffer, pH 8.0	to 8 µl

*All entry clones (two, three or four, depending on the type of reaction) must be included. The total of all entry clones combined should not exceed 7 µl.

LR Reaction Procedure

1. Remove LR Clonase™ II Plus enzyme mix from freezer and thaw on ice for about 2 minutes. Vortex the enzyme mix briefly twice (2 seconds each).
2. To each MultiSite or MultiSite Pro LR reaction mixture, add 2 µl of LR Clonase™ II Plus and mix well by vortexing briefly twice. Microcentrifuge briefly.
3. Return enzyme mix to freezer immediately after use. The enzyme mix can be stored at -20°C for up to 6 months or at -80°C for long-term storage.
4. Incubate recombination reaction at 25°C for 16 hours.
5. Add 1 µl of the Proteinase K solution to each sample to terminate the reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes.

Transformation

1. For 2- or 3-fragment recombination reactions, add 2 µl to 50 µl of One Shot® Mach1™ T1^R Chemically Competent *E. coli* and incubate on ice for 30 minutes.
2. For 4-fragment recombination reactions, add 4 µl to 50 µl of One Shot® Mach1™ T1^R Chemically Competent *E. coli* and incubate on ice for 30 minutes.
3. Heat-shock cells by incubating at 42°C for 30 seconds.
4. Immediately transfer the tubes to ice for 2 minutes.
5. Add 250 µl of S.O.C. medium and incubate at 37°C for 1 hour with shaking at 225 RPM.
6. For 2-fragment recombination reactions, dilute 1:10 in S.O.C. medium and plate 50 µl and 100 µl of each transformation on prewarmed LB plates containing 50-100 µg/ml antibiotic of choice, invert and incubate overnight at 37°C. For 3-fragment recombination reactions, plate 50 µl and 100 µl of each transformation as above. For 4-fragment recombination reactions, spin at 6,000 rpm, remove 180 µl of supernatant and gently resuspend the pellet in the residual media. Plate entire reaction as above.

Typical Numbers of Colonies (per 10 µl reaction):

2-fragment recombination reaction:	2,000-15,000
3-fragment recombination reaction:	1,000-5,000
4-fragment recombination reaction:	50-500